Loading…
Company achieves key genetic engineering milestone.
BriaCell Therapeutics Corp. (Nasdaq: BCTX) announced on August 24, 2026, that its personalized whole cell melanoma immunotherapy vaccine candidate, Bria-MEL+, has achieved a key genetic engineering milestone. This advancement moves the program closer to clinical development.
The announcement highlighted that approximately 112,000 new cases and 8,510 deaths are expected from melanoma in the relevant year. The company's progress in genetic engineering is a significant step toward addressing this critical healthcare need.
As of the latest data, BriaCell Therapeutics Corp. has 7,859,562 shares in free float and 8,699,787 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.